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Received December 9, 2011; accepted April 2, 2012AbstractBackground: Adequate adjuncts help to reduce the volume of polyethylene glycol-electrolyte lavage solution (PEG-ELS) needed, to ameliorate
patient discomfort, and to improve colonic visibility during colonoscopy. This study aimed to assess the effect of Citrus reticulata peel (CRP) as
an adjunct to low-volume PEG for colonic preparation.
Methods: A total of 1092 health examination examinees received colonoscopy during the study period. After excluding those who refused to
participate and those who did not meet our criteria, 212 examinees were enrolled into this study. They were divided into the PEG group and the
PEG þ CRP group according to their date of examination. All examinees received 2 L of PEG-ELS one day before colonoscopy. The
PEG þ CRP group also received additional CRP in the form of a “buccal tablet” between drinks. Tolerance and adverse events were assessed by
questionnaire, while the quality of bowel preparation for colonoscopy was scored by an endoscopist.
Results: There were 107 examinees in the PEG group and 105 examinees in the PEG þ CRP group. The demographic characteristics of the
examinees were comparable between these two groups. Examinees in the PEG þ CRP group had a trend of better colonic visibility than those in
the PEG group ( p ¼ 0.056). Moreover, examinees in the PEG þ CRP group had higher rate of acceptable taste ( p ¼ 0.015) and lower rate of
difficulty swallowing ( p ¼ 0.001). The incidences of adverse events including vomiting ( p ¼ 0.045), bloating ( p ¼ 0.035), and difficulty
sleeping ( p < 0.001) were also significantly lower in the PEG þ CRP group.
Conclusion: Compared with conventional colonic preparation, the application of CRP as an adjunct could improve examinees’ tolerance,
decrease the incidence of adverse events, and maintain the quality of colonic cleansing.
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During colonoscopy, sufficient bowel preparation is
essential for detecting small lesions and visualizing the
mucosa. However, colonoscopy preparation regimens are
either poorly tolerated by patients because of the large volume
of polyethylene glycol-electrolyte lavage solution [(PEG-
ELS)] or the risk of electrolyte imbalance and hemodynamic
instability (from sodium phosphate). Such challenges limit the
clinical application of sodium phosphate and full-dose PEG-
ELS.1
Low-volume PEG combined with adjunctive laxatives has
been shown to be comparable to full-dose PEG in terms of
colonic preparation quality and better patient tolerance.2e7
Adjuncts such ascorbic acid, bisacodyl, and olive oil have
been demonstrated in recent trials to be effective in achieving
colonic visibility and patient tolerance.2,3,8 However, anorexia,
vomiting, bloating, and abdominal pain still affect a substan-
tial number patients who receive bisacodyl as an adjunct for
colonic preparation, and this may compromise the quality of
colonic cleansing.
In this study, we evaluated Citrus reticulata peel (CRP),
dried tangerine peel, as an adjunct for colonoscopy prepara-
tion. Citrus peel is commonly used for flavoring food and
beverages worldwide. CRP is the dried pericarp of the ripe
fruit of Citrus reticulata Blanco, and its main indications in
traditional medicine include bloating, anorexia, and vomit-
ing.9,10 We deduced that adding CRP to a conventional colon
preparation of low-volume PEG-ELS with bisacodyl could
improve the quality of colonic cleansing by reducing the side
effects produced by the bisacodyl. To validate this hypothesis,
we conducted a prospective study comparing the quality of
colonic cleansing and examinees’ satisfaction with a conven-
tional low-volume preparation against one with added CRP.
2. Methods2.1. ExamineesFig. 1. Citrus reticulata peel in a 2 g piece.We enrolled examinees who were visiting Taipei Veterans
General Hospital for health examination during the period
May 22, 2009 to September 25, 2009. The exclusion criteria
were: the presence of serious conditions such as severe
cardiac, pulmonary, renal, hepatic, or metabolic diseases;
active alcoholism, drug addiction, or major psychiatric illness;
known allergy to PEG-ELS; and refusal to participate. Oral
and written instructions about the colonic preparation were
given to all examinees.
After obtaining informed consent, examinees were assigned
to either the PEG group (conventional preparation using low-
volume PEG-ELS with bisacodyl) or the PEG þ CRP group
(conventional preparation with additional CRP) according to
their date of colonoscopy examination. Examinees in the PEG
group were enrolled fromMay 22, 2009 to July 28, 2009, while
those in the PEG þ CRP group underwent colonoscopy from
July 29, 2009 to September 25, 2009. The hospital’s institutional
review board approved the study protocol (98-03-05A).2.2. Preparation instructionsEach pack of low-volume PEG-ELS (Niflec; China
Chemical & Pharmaceutical Co., Ltd. Taiwan, R.O.C.) con-
tained 82.9 g sodium sulfate anhydrous, 21.36 g sodium
chloride, 10.83 g potassium chloride, 24.57 g sodium bicar-
bonate, and polyethylene glycol 4000 for a total of 137.155 g.
All examinees received one pack of Niflec in 2 L of water
1 day before the procedure and were asked to drink one glass
of solution (250 mL) every 10e15 minutes, starting at 4 PM,
until the 2 L had been consumed (within 2 hours). They were
also instructed to begin a clear liquid diet on the morning of
the day before colonoscopy and to fast after midnight.
The PEG þ CRP group received additional CRP between
drinks (every 10e15 minutes after completing 250 mL of
solution) with one piece (2 g) of CRP (Fig. 1). Examinees
were instructed to place the CRP between the hard palate and
tongue rather than swallowing it. After 5 minutes with this in
place, they had to spit out the remaining CRP and continued
with the preparation solution. Eight pieces of CRP were given
for every colonoscopy preparation.
All examinees received 15 mg bisacodyl after the first time
they had diarrhea or at 8 PM on the same day if there was no
bowel movement. All examinees were also asked to drink
sports drinks or warm water after completing the entire
preparation solution (but not exceeding 3500 mL in total
volume).2.3. ColonoscopyAfter the examinee had undergone successful conscious
sedation, the endoscopist waiting in the preparing room was
informed to perform the colonoscopy. The endoscopist and
technicians were blinded to the correlation between the study
periods and the preparation regimen. All colonoscopies were
performed in the morning, and examinees were continuously
monitored (heart rate and oxygen saturation) during the
procedure and recovery period. The quality of bowel cleansing
was graded by the endoscopist at the end of the procedure
according to a previously described scale. (Table 1).11,12
Table 1
Grading system for evaluating colonoscopic bowel cleansing.
Grade Comment Description
1 Excellent Small volume of clear liquid or >95% of surface visible
2 Good Large volume of clear liquid covering 5e25% of the surface but >90% of the surface visible
3 Fair Some semisolid stool that could be suctioned off or washed away, but >90% of the surface visible
4 Poor Semisolid stool that could not be suctioned off or washed away, with <90% of the surface visible
5 Very poor Repeated preparation needed
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Secondary study end-points included adverse events and patient
tolerability, which were evaluated at the time before colono-
scopy. The onset time (from the first dose of PEG-ELS to the first
time the patient had diarrhea) and total duration of preparation
solution action (from the time of first diarrhea to the last diarrhea
after drinking PEG-ELS) were also calculated.2.5. Data collectionBefore the colonoscopy, each examinee was interviewed by
our nursing staff to evaluate the acceptability of the preparation
(i.e. taste, ease of swallowing, and percentage of incompletely
consumed preparation solution) and adverse events, including
bloating, nausea, vomiting, abdominal cramps, and sleep
disturbances. Our study nurses responsible for data collection
were blinded to examinee allocation. After instructing exam-
inees how to fill out the questionnaires, study nurses let exam-
inees rank their discomfort during the preparation (on a scale of
1e5, with 1 representing “Very Difficult” to 5 representing
“Very Easy”) and fill out the questionnaires themselves.2.6. Statistical analysisSample size calculation was based on the assumption of
a 70% satisfactory preparation (excellent, good, or fair) in the
PEG group and 85% in the PEG þ CRP group, respectively,
by using the Z-statistic to compare dichotomous variables,
with a ¼ 0.05 (two-tailed) and b ¼ 0.20. The estimated
sample size was 95 examinees per arm. Keeping in mind
a likely drop-out rate of 10%, at least 105 examinees were
required in each group.
Pearson Chi-square analysis or Fisher’s exact test were used
to compare categorical variables, while the ManneWhitney U
test was used to compare continuous variables. A two-tailed
p < 0.05 was considered to be statistically significant. All
statistical analyses and database collection were performed
using the Statistical Package for Social Sciences (SPSS 17.0
for Windows; SPSS Inc., Chicago, IL, USA).
3. Results3.1. Demographic characteristicsA total of 1092 health examination examinees received
colonoscopy during this study period. After excluding thosewho refused to participate and those who did not meet our
criteria, 212 examinees were enrolled into this study. There
were 107 examinees in the PEG group and 105 in the
PEG þ CRP group (Fig. 2). These two groups were compa-
rable in terms of age, gender, height, body weight, chronic
constipation, abdominal surgery, and the co-morbidities of
hypertension and diabetes mellitus (Table 2). All colonos-
copies were completed to the level of the cecum. The number
of examinees with prior colonoscopy and those who had
received medication that could interfere with the adequacy of
bowel preparation were also similar in both groups (Table 2).3.2. Onset, action, and tolerance of preparation solutionCompliance with the preparation was better in the
PEG þ CRP group than that in the PEG group, as demon-
strated by significantly higher rates of acceptable taste (85.7%
versus 71%; p ¼ 0.015) and lower rates of difficulty swal-
lowing (8.6% versus 27.1%; p ¼ 0.001) (Table 3). The onset
time was similar in both groups (66.4 minutes versus 73.0
minutes; p ¼ 0.213). Regarding the mean duration from first
diarrhea to last diarrhea after drinking PEG-ELS, a signifi-
cantly shorter time was noted in the PEG þ CRP group
compared with the PEG group (6.3 hours in PEG þ CRP
group versus 8.0 hours in PEG group; p ¼ 0.001). In addition,
the percentage of incompletely consumed preparation solution
was similar in both groups (2.9% versus 0%; p ¼ 0.238).3.3. Adverse eventsCompared with the PEG group, the incidence of adverse
events with colonoscopy preparation was significantly lower in
the PEG þ CRP group, as shown by a statistically lower rate
of vomiting (7.2% in the PEG þ CRP group versus 17.8% in
the PEG group; p ¼ 0.045), lower rate of bloating (81.9%
versus 92.5%; p ¼ 0.035), and lower rate of difficulty sleeping
(6.7% versus 34.6%; p < 0.001). Other side effects including
nausea, abdominal cramping, headache, and dizziness were
comparable between the two groups (Table 4).3.4. Quality of colonic cleansingThe quality of the colonic cleansing was comparable in
both groups with regard to the overall percentage and number
of satisfactory preparations (Table 5). In the PEG þ CRP
group, 95 examinees (90.5%) had a satisfactory preparation
(defined as excellent, good, or fair) compared with 86
Fig. 2. Flow chart of enrolled examinees.
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CRP use ( p ¼ 0.059) (Table 5).
4. Discussion
Colorectal cancer is the second leading cause of cancer
mortality worldwide and accounts for approximately 9% of
overall cancer mortality.13e15 It is estimated that attaining the
goals for population colorectal cancer screening can save
18,800 lives per year in the United States.13 Colonoscopy is
considered the standard against which the sensitivity of other
colorectal cancer screening tests should be compared.15
Thorough colonoscopy depends on adequate bowel prepara-
tion, and around one-fifth to one-third of failed procedures are
due to poor preparation.16,17 The quality of bowel preparation
also has a direct impact on the adenoma detection rate.18e20Table 2
Demographic data of the study examinees.
Variables PEG group (n ¼ 1
Age (y) 55.5  10.1
Sex male/female 64/43 (59.8/40.2)
Body height (cm) 164.1  8.5
Body weight (before preparation) (kg) 68.0  14.1
Body mass index (kg/m2) 25.11  4.13
Hypertension 33 (30.8)
Diabetes mellitus 9 (8.4)
Abdominal surgerya 30 (28)
Chronic constipation 18 (16.8)
Medication may alter preparation adequacyb 9 (8.4)
Prior colonoscopy 33 (31.0)
Continuous variables are expressed as mean  SD; categorical variables are expre
CRP ¼ Citrus reticulata peel; PEG ¼ polyethylene glycol; SD ¼ standard deviati
a Includes cholecystectomy, gastrectomy, appendectomy, and total hysterectomy
b Includes insulin, narcotics, hypoglycemic agents, and antidepressants.However, during colonic preparation, colonic visibility,
patient tolerance, and safety are often difficult to achieve.
According to the American Society for Gastrointestinal
Endoscopy consensus statement, “Physicians favor prepara-
tions associated with best patient compliance in order to
achieve the best results. Patients favor preparations that are
low in volume, palatable, and have easy to complete regi-
mens.”21 Unfortunately, such conflicts limit the clinical
application of preparation solutions.
Standard full-dose PEG-ELS has little effect on electro-
lytes, but patients have to tolerate the abdominal fullness,
nausea, and vomiting associated with the large lavage volume.
Sodium phosphate solution, although much smaller in volume,
is not suggested for the elderly or those with heart failure,
impaired renal function, uncontrolled hypertension, or ascites
due to risk of electrolyte imbalance and hemodynamic07) PEG þ CRP group (n ¼ 105) p
54.4  9.0 0.398
61/44 (58.1/41.9) 0.909
163.6  7.1 0.619
64.9  10.8 0.077
24.16  3.10 0.060
24 (22.9) 0.248
9 (8.6) 1.000
21 (20) 0.227
11 (10.5) 0.252
9 (8.6) 1.000
38 (36.2) 0.500
ssed as numbers (%).
on.
with bilateral salpingo-oophorectomy.
Table 3
Onset, action, and tolerance of colon preparation solution between the PEG group and the PEG þ CRP group.
PEG group (n ¼ 107) PEG þ CRP group (n ¼ 105) p
Onset (minutes) 66.4  40.6, 7.0e210 73.0  35.4, 15e150 0.213
Duration of action of preparation solution (hours) 8.0  3.6, 1.5e19.7 6.3  3.8, 1.5e17.4 0.001
Acceptable taste 76 (71) 90 (85.7) 0.015
Difficult of swallowing 29 (27.1) 9 (8.6) 0.001
Incomplete preparation solution 0 (0) 3 (2.9) 0.238
Continuous variables are expressed as mean  SD, range; categorical variables are expressed as numbers (%).
CRP ¼ Citrus reticulata peel; PEG ¼ polyethylene glycol.
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one of the strategies is to add an adjunct to reduce the PEG
volume. Low-volume PEG combined with adjunctive laxatives
is shown to have comparable colonic preparation quality and
better patient tolerance than full-dose PEG.4e7 This strategy is
recommended by current guidelines.21,22
Another reason for choosing reduced PEG plus bisacodyl in
health examinations is its ease of dosing and the greater
convenience it affords to patients.23 Adjuncts such as ascorbic
acid, olive oils, and reduced dose bisacodyl are all proven to
have sufficient efficiency.2,3,8 However, in clinical practice,
even patients who receive reduced PEG-ELS with bisacodyl
still suffer from nausea, vomiting, bloating, and abdominal
pain. Consequently, it has become necessary to evaluate the
efficacy of Citrus reticulata peel as an additional adjunct for
colonoscopy preparation.
Citrus peel is widely used for flavoring food and beverages
worldwide.24,25 According to one report in the US state of
Arizona, in people that had the habit of regularly consuming
citrus fruits or citrus juice, peel consumption itself was also
relatively common, at around 34.7%.26 Citrus peel is rich in
flavonoid glycosides that have awide range of biological effects
in vitro and in vivo, including antioxidant, anti-inflammatory,
and anti-carcinogenic properties.27 Epidemiological evidence
suggests that citrus peel consumption may provide protection
against coronary heart disease28e31 and stroke.32 Citrus flavo-
noids include hesperidin, neo-hesperidin, nobiletin, tangeritin
and so on.33 Like other fruits, citrus peel is rich in electrolytes,
minerals, and vitamins, especially vitamin C.34
In East Asia, citrus peel has been used in traditional herbal
medicines for a long time.35 CRP is well documented for its
prokinetic, anti-bloating and appetite- improving effects.36e38Table 4
Comparison of adverse events in colonic preparations between the PEG group
and the PEG þ CRP group.
Symptoms PEG group
(n ¼ 107)
PEG þ CRP
group (n ¼ 105)
p
Nausea 20 (18.7) 18 (17.1) 0.909
Vomiting 19 (17.8) 8 (7.2) 0.045
Abdominal
cramping pain
4 (3.7) 11 (10.5) 0.100
Bloating 99 (92.5) 86 (81.9) 0.035
Headache 24 (22.4) 29 (27.6) 0.475
Dizziness 6 (5.6) 13 (12.4) 0.137
Difficulty sleeping 37 (34.6) 7 (6.7) <0.001
Data are presented as number (%).
CRP ¼ Citrus reticulata peel; PEG ¼ polyethylene glycol.In previous clinical studies, it significantly improved cancer
patients’ appetite and effectively relieved delayed gastric
emptying.39,40 Based on those background data, we decided to
conduct this prospective study to compare the conventional
preparation solution (PEG group) against one with CRP
(PEG þ CRP group) in terms of the quality of colonic
cleansing, compliance, and adverse effects.
Using a rating questionnaire, significantly more examinees
accepted the taste (85.7% versus 71%; p ¼ 0.015) and fewer
examinees had difficulty in swallowing (8.6% versus 27.1%;
p ¼ 0.001) in the PEG þ CRP group. Also, the side effects and
discomfort were significantly reduced in the PEG þ CRP
group, as evidenced by the lower rates of vomiting
( p ¼ 0.045), bloating ( p ¼ 0.035), and difficulty sleeping
( p < 0.001). Taken together, this suggests that CRP could
serve as an adjunct to reduce the discomfort of patients
receiving colonic cleansing.
Is it the flavor, the taste or CRP’s prokinetic effect that
directly impacts on the preparation result? There are a number
of factors that may explain this phenomenon. First, during
bowel preparation, the unpleasant salty taste (mostly related to
sodium phosphate) and large volume (mostly PEG related) are
the major causes of side effects (nausea and vomiting).22 In
clinical settings for PEG preparation, patients were encour-
aged to consume the solution completely with a flavored clear
liquid diet. Some commercial preparation solutions also come
in a form with different types of flavor for patients. However,
most of these patients still suffered from abdominal fullness,
bloating, nausea, and vomiting despite alteration of the
unpleasant taste.21 Thus, it would appear that the side effects
from PEG are often volume-related and could not be improved
by flavor in our clinical observation.Table 5
Comparison of colonoscopy visibility between the PEG group and the
PEG þ CRP group.
Grade PEG group PEG þ CRP group
(n ¼ 107) (n ¼ 105)
Satisfactory Excellent 11 (10.3) 9 (8.6)
Good 40 (37.4) 44 (41.9)
Fair 35 (32.7) 42 (40.0)
Unsatisfactory Pool 21 (19.6) 10 (9.5)
Failed 0 (0) 0 (0)
Data are presented as number (%).
p ¼ 0.059, satisfactory versus unsatisfactory.
CRP ¼ Citrus reticulata peel; PEG ¼ polyethylene glycol.
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aration quality between flavored and unflavored PEG solution.
They did not mention whether the flavored group had less
discomfort and fewer side effects.41 Third, the PET þ CRP
group in fact showed a significantly shorter duration of action
than the PEG group ( p ¼ 0.001), indicating that the prokinetic
effects of CRP rather than the flavor may better explain the
decreasing duration of action of the preparation solution,
reducing the volume-related side effects and facilitating the
smoother consumption of PEG.
The high percentage of bloating rate in both groups
(81.9e92.5%) may be due to the usage of bisacodyl at a dose
of 15 mg.42 The symptoms improved for examinees in the
PEG þ CRP group when CRP was applied. Moreover,
examinees in the PEG þ CRP group showed a much shorter
duration of action of the preparation solution compared with
those in the PEG group ( p ¼ 0.001). Although CRP has not
been reported to have an indication for insomnia, it also
improved difficulty sleeping during colonoscopy preparation
in this study. This effect may directly result from the shorter
duration of action in the PEG þ CRP group, thus not depriving
examinees’ of their sleeping time.
Additionally, the effect may be indirect through less vom-
iting and bloating. Vomiting is an important and critical issue.
The salty taste, large volume of solution applied, and patients’
underlying disease are all common causes of vomiting. It
should be noted that it is difficult to calculate the volume of
vomitus in these studies. Thus, patients who suffer from severe
vomiting may be left with under the recommended dose of
PEG-ELS, which in turn lowers the quality of preparation.43
There was no statistically significant difference in colonic
visibility between the two groups. However, there was a trend
favoring CRP use when the results were dichotomized as
satisfactory (excellent, good, and fair results together) or
unsatisfactory (poor and very poor results together) for colonic
visibility (90.5% versus 80.4%; p ¼ 0.059). This trend may be
due to the summation of the prokinetic effects of CRP 9,10 and
improved examinee tolerance and compliance. In comparison,
the percentage of good to excellent preparations in our cohort
(47.7% for PEG versus 50.5% for PEG þ CRP) is inferior to
the results of previous reports (86.2e88.0%).2,6
In those studies, investigators started their PEG-ELS
treatment from 6e9 PM, and patients received colonoscopy
the following morning. However, after considering examinees’
compliance and convenience when undergoing such health
examinations, our examinees received their PEG-ELS dosing
at 4 PM. Consequently, the duration from PEG-ELS dosing
time to colonoscopy initiation time was around 15e18 hours,
which is longer than the times applied in the previous studies
(9e12 hours). This may greatly influence the preparation
quality as a result of intestinal shedding,44 which may explain
the difference between current and previous studies. Further-
more, the effect of CRP might have been countervailed by the
long duration of bowel preparation prior to examination.
Our study had a number of limitations that should be noted.
First, it was difficult to establish a placebo that resembled the
appearance, smell, and texture of CRP in this study. The lackof a placebo group in order to detect a placebo effect could be
a weakness. Second, this study was not a double-blinded
randomized controlled study; although we had objective
evidence (quality of preparation) as our primary end- points,
patients in the PEG þ CRP group may have been influenced
by the Hawthorne effect. However, the endoscopists were also
blinded to the grouping of colonoscopy preparation. This may
have helped to reduce the bias in assessing the degree of colon
cleansing, which was the primary end-point of our current
study. Third, the component of CRP responsible for the
gastrointestinal prokinetic effects remains unknown. To
quantify these findings with regard to clinical practice, further
study may be required to investigate which component is
responsible for this effect.
In conclusion, when compared with conventional colonic
preparation, the use of CRP as an adjunct can improve
examinee tolerance, decrease the incidence of adverse events,
and maintain the quality of colonic cleansing.Acknowledgments
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